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INTRODUCTION
Glioblastoma multiforme (GBM) tumor cells in-
filtrate deeply into surrounding brain tissue and may
even reach the contralateral hemisphere. After a
decade of intensive research, these cells remain ex-
tremely resistant to all current forms of therapy in-
cluding surgery, chemo-, radio-, immuno-, and gene
therapy. The new anti-cancer drug temozolomide
(TMZ) improved clinical outcomes. Randomized
clinical trials of TMZ and radiotherapy (RT) vs. RT
alone showed that the median survival was 14.6
months with combined therapy and 12.1 months in
GBM patients receiving radiotherapy alone (1, 2).
Overall survival was 27.2% at 2-, 16.0% at 3-, 12.1% at
4-, and 9.8% at 5 years in patients treated with TMZ ;
it was 10.9%, 4.4%, 3.0%, and 1.9%, respectively, in
GBM patients subjected to radiotherapy alone (3).
Boron neutron capture therapy (BNCT) is based
on the nuclear capture and fission reactions that oc-
cur when boron-10, a non-radioactive constituent
of the natural elemental boron, is irradiated with
low-energy (0.025 eV) thermal neutrons. This re-
sults in the production of high linear energy transfer
(LET) alpha particles (4He) and the recoiling of lith-
ium-7 (7Li) nuclei as shown below and in Fig. 1.
10B + nth (0.025 eV)
[11B]
4He + 7Li 2.79 MeV 6%
4He + 7Li 2.31 MeV + γ 0.48 MeV 94%
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For successful therapy, a sufficient amount of 10B
must be selectively delivered to all tumor cells and
enough thermal neutrons must be absorbed to pro-
duce lethal damage from the 10B(n,α)7Li capture re-
action. The destructive effects of these high-energy
particles are limited to boron-containing cells and
since their path-length in tissues is very short (5-9
μm), theoretically, BNCT provides a way to selec-
tively destroy malignant cells while sparing adjacent
normal cells (Fig. 1). As BNCT offers the possibil-
ity of selective tumor-cell killing without damag-
ing adjacent normal brain tissue, it may be an opti-
mal treatment for GBM, which is highly invasive to
healthy normal tissue (4-6). In 1968, Hatanaka in-
troduced sodium borocaptate (BSH) as a boron car-
rier in Japan ; this started the treatment of GBM
patients with BNCT combined with BSH and pure
thermal neutrons, and established BSH-based in-
traoperative BNCT (IO-BNCT) (7). Because ther-
mal neutron beams have a limited depth of penetra-
tion in tissue, it is necessary to reflect the skin and
to raise the bone flap to irradiate the exposed brain
directly. This eliminates radiation damage to the
scalp and permits treatment of deep-seated residual
brain tumors.
The clinical outcomes of IO-BNCT were unsat-
isfactory in patients whose brain tumor was situ-
ated in deeper regions because neutron fluence
delivery into the deep regions was inadequate (7-
11). Therefore, epithermal neutron beams were de-
veloped to improve neutron delivery (11, 12) and a
new dose-evaluation system for BNCT, the Japan
Atomic Energy Research Institute (JAERI) Compu-
tational Dosimetry System (JCDS) was created. It
allows evaluation of the BNCT radiation dose on
computed tomography- and magnetic resonance im-
aging (MRI) scans (13, 14). In addition, it facilitates
achieving the appropriate head position and -angle
with respect to the neutron beam port during irra-
diation. In 2004, boronophenylalanine (BPA), a new
boron compound that is actively taken up by tumor
cells (15), was introduced for the treatment of GBM
with BNCT. The introduction of the epithermal neu-
tron beam, the clinical use of BPA, and the dose
planning system of JCDS made the clinical use of
nonoperative BNCT (NO-BNCT) combined with
BSH and BPA a reality. We changed from IO-BNCT
to NO-BNCT in 2005.
Recent clinical studies on NO-BNCT have focused
on high-grade gliomas, malignant meningiomas,
head and neck cancers, cutaneous melanomas, and
lung- and liver metastasis as potential candidates
for BNCT.
Figure 1 Principles of boron neutron capture therapy (BNCT).
Left : BNCT is based on the nuclear capture and fission reactions that occur whenboron-10, a non-radioactive constituent of the natural
elemental boron, is irradiated with low-energy (0.025 eV) thermal neutrons. This result in the production of high linear energy transfer
(LET) alpha particles (4He) and the recoiling of lithium-7 (7Li) nuclei.
Right : The destructive effects of these high-energy particles are limited to boron-containing cells. Since they have a very short path-
length in tissues (5-9 μm), in theory, BNCT provides a way to selectively destroy malignant cells and spare adjacent normal cells.
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METHODS AND MATERIALS
Dose planning and evaluation
The BNCT radiation dose was evaluated based
on the physical boron dose (Gy) and the weighted
dose (Gy(w)) using JCDS. Based on the BNCT ra-
diation dose we applied a new concept of BNCT to
the physical radiation dose of the boron n-α reac-
tion. To compare the radiation effect of the two
heavy particles and to evaluate the efficacy of BNCT
we determined the physical radiation dose of the
boron n-α reaction (11). The weighted dose was cal-
culated by multiplying the weighting factors to ac-
count for the increased biological effectiveness of
the high-LET dose components, α and 7Li particles,
through the boron neutron capture reaction.
Patients and protocols
The ethics committee of the Graduate School of
Health Biosciences, the University of Tokushima,
approved this study ; prior informed consent was ob-
tained from all participating patients.
Between 1998 and 2005 we treated 23 newly di-
agosed GBM patients with BNCT ; they included 17
patients who underwent BSH-based IO-BNCT, and
6 patients subjected to BSH and BPA-based NO-
BNCT. To be enrolled in this study, patients had to
satisfy all of the following criteria : their glioma was
diagnosed as glioblastoma (grade IV), they had no
serious systemic diseases, and their general condi-
tion was good according to the Karnofsky Perform-
ance Scale (KPS70). No patient subjected to BNCT
received additional radiotherapy or chemotherapy
after BNCT. Our institutional controls were 34 newly
diagnosed GBM patients treated by external con-
ventional radiotherapy (RT) with concomitant and
adjuvant temozolomide (TMZ) between 2006 and
2009 at Tokushima University Hospital.
BNCT procedure and JCDS measurements
For IO-BNCT, 12-15 hours before neutron irradia-
tion we delivered 100 mg/kg BSH via intravenous
(iv) infusion within 60 min. On the day of BNCT we
performed craniotomy under general anesthesia to
target the neutron beam directly on the tumor tis-
sue. For NO-BNCT we used a combination of 100
mg/kg BSH and 250 mg/kg BPA. BSH and BPA
were administered iv within 60 min 12 hours and 1
hour before irradiation, respectively. The neutron
beam was irradiated directly through the skin under
local anesthesia. The boron concentration in blood
and tumor tissue was measured immediately using
gamma-ray spectroscopy.
Survival analysis
We compared the median survival time (MST)
from the initial surgery between BNCT patients
and our institutional historical controls, i.e. patients
treated with debulking surgery followed by exter-
nal conventional RT and chemotherapy. Estimates
of survival propability were calculated using the
Kaplan-Meier method.
We also compared the survival time of our 23
BNCT patients with the survival of international
historical controls, i.e. corresponding recursive par-
titioning analysis (RPA) subclasses as defined by
the European Organization of Research and Treat-
ment of Cancer (EORTC) (16) (RPA class III : age
50, GBM, WHO performance status 0, class IV :
age50, GBM, WHO performace status 1-2 or age
50, GBM, complete/partial surgery, Mini-Mental




IO-BNCT was performed in 17 GBM patients
(1998, n=6 ; 2001, n=11), NO-BNCT in 6. The pa-
tient age and the results of RPA for BNCT alone and
for RT+TMZ obtained at Tokushima University Hos-
pital are shown in Table 1.
The mean post-diagnosis follow-up period for all
23 patients was 30 months (range 5-111 months).
All but one patient died from cerebrospinal fluid
(CSF) dissemination (n=4), tumor invasion to the
brain stem (central nervous system (CNS) dissemi-
nation, n=2), both CSF and CNS dissemination (n=
1), local recurrence and CSF dissemination (n=1),
suspected local recurrence and/or radiation necrosis
(no histopathological verification, n=4), wound in-
fection (n=2), distinct metastasis (n=1), local recur-
rence (n=5), unknown causes (n=1), or acute myo-
cardial infarction (n=1). CSF and/or CNS dissemi-
nation without local recurrence at the primary site
was the cause of death in 7 of 21 patients (33%).
MST and survival rate in patients treated by
BNCT or RT+TMZ
The MST in patients treated by BNCT (n=23)
was 19.5 months ; the 2-, 3-, and 5-year survival
rate was 31.8%, 22.7%, and 9.1%, respectively. The
MST in patients receiving RT+TMZ (n=34) was
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 13.5 months ; the 2- and 3-year survival rate was
27.5% and 16.5%, respectively. There was no statis-
tically significant difference (p=0.25) between the
two groups with respect to the survival probability
estimates (Fig. 2).
The MST in patients subjected to IO-BNCT or
NO-BNCT was 17.4 and 24.2 months, respectively ;
the 2-, 3-, and 5-year survival rates were 23.5% and
50.0%, 23.5% and 16.7%, and 5.9% and 16.7%, respec-
tively. There was no statistically significant difference
Table 1 : Summary of patients treated by BNCT alone and by RT+TMZ at Tokushima University Hospital between 1998 and 2009
BNCT alone group RT+TMZ group
Number of patients 23 34
age 4721 5914
Above 70 2/23 (9%) 11/34 (32%)
Below 15 2/23 (9%) 0 (0%)
Surgical radicality
GTR 1 (4%) 1 (3%)
STR 7 (30%) 15 (44%)
PR 15 (65%) 8 (24%)
Biopsy 0 (0%) 8 (24%)
No surgery 0 (0%) 2 (6%)
RPA classification
III 8 (35%) 2 (6%)
IV 8 (35%) 13 (38%)
V 7 (30%) 19 (56%)
BNCT : boron neutron capture therapy, RPA : recursive partitioning analysis, RT : radiotherapy,
TMZ : temozolomide
GTR : gross tumor removal, STR : subtotal tumor removal, PR : partial tumor removal
Figure 2 Kaplan Meier curves of patients treated with BNCT alone (n=23) or with RT+TMZ (n=34).
There was no statistically significant difference between patients who underwent BNCT alone and patients treated with RT+TMZ in
the survival probability estimates (p=0.25).
BNCT, boron neutron capture therapy ; RPA, recursive partitioning analysis ; RT, radiotherapy ; TMZ, temozolomide.
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 (p=0.41) between the two groups with respect to
the survival probability estimates.
MST and survival rate in RPA-subclassified pa-
tients treated by BNCT or RT+TMZ
Of the 23 patients treated by BNCT, 8 each were
in RPA subclass 3 and 4 ; the other 7 were in RPA
subclass 5. MST in RPA 3-, 4-, and 5 patients was
17.4-, 20.6-, and 11.9 months, respectively (Table 2).
The 2-, 3-, and 5-year survival rates were 37.5%,
37.5%, and 16.7%, (RPA 3), 37.5%, 12.5%, and 0%
(RPA 4), and 18.8%, 0% and 0% (RPA 5).
In our series, of the 34 patients treated with RT+
TMZ, 2 were subclassified as RPA 3, 13 as RPA 4,
and 19 as RPA 5. The MST for RPA 4 and RPA 5
patients was 24.2 and 12.8 months, respectively
(Table 2). The 2- and 3-year survival rate in RPA 4
and RPA 5 patients was 29.5% and 17.1%, and 29.5%
and 9.0%, respectively. There was no statistically
significant difference between patients subjected
to BNCT or RT+TMZ with respect to the survival
probability estimate of patients in subclasses RPA 4
(Fig. 3) (p=0.91) and RPA 5 (p=0.84) (Fig. 4).






RT+TMZ group BNCT alone group
n months n months n months
RPA 3 42 18.7 2 NE 8 17.4
RPA 4 152 16.3 13 24.2 8 20.6
RPA 5 93 10.7 19 12.8 7 11.9
overall 287 14.6 34 13.5 23 19.5
BNCT, boron neutron capture therapy ; RPA, recursive partitioning analysis ; RT, radiotherapy ;
TMZ, temozolomide ; NE, not evaluated ; n, number of patients
aMirimanoff RO et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma : Recursive partitioning analysis of the
EORTC26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 24 : 2563-2569, 2006
bStupp R et al. Effect of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma
in a randomized phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10 : 459-466, 2009
cOur study of 23 newly diagnosed GBM patients treated with BNCT. It included 17 patients treated with IO-BNCT and 6 patients treated
with NO-BNCT between 1998 and 2005. It also included 34 newly diagnosed GBM patients who were treated by external conventional
radiotherapy and temozolomide (TMZ) between 2006 and 2009 at Tokushima University Hospital.
Figure 3 Kaplan Meier curves of patients treated with BNCT alone (n=8) or with RT+TMZ (n=13) who were subclassified as RPA 4.
There was no statistically significant difference between the two patient groups in the survival probability estimates (p=0.91).
BNCT, boron neutron capture therapy ; RPA, recursive partitioning analysis ; RT, radiotherapy ; TMZ, temozolomide.
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 DISCUSSION
The mechanism of selective boron uptake in tu-
mor cells was reported as follows : BSH cam pass
through the disrupted blood-brain-barrier easily and
boron can be internalized into cells in endocytic
pathways after binding to the plasma membrane
(17). BPA is incorporated into tumor cells via a me-
tabolism pathways of amino acids (18). The destruc-
tive effects of these high-energy particles are lim-
ited to boron-containing cells and since they have
very short path-lengths in tissues (5-9 μm), theo-
retically, BNCT provides a way to selectively destroy
malignant cells while sparing adjacent normal cells
(4-6). As BNCT may facilitate the selective killing of
tumor cells without damaging adjacent normal brain
tissue, it may be an optimal treatment for GBM,
which is highly invasive to healthy normal tissue.
The first clinical trials were carried out in 1951
by Sweet at Massachusetts General Hospital, by
Brownell at the Massachusetts Institute of Technol-
ogy, and by Farr at the Brookhaven National Labo-
ratory in New York. They used sodium tetraborate
(borax), sodium pentaborate, p-carboxyphenylboroic
acid, or sodium decahydrodecaborate as the sole
boron delivery agent and thermal neutron beams as
the neutron. However, their results were discourag-
ing because none of their patients survived for one
year. Hatanaka (5) and Barth et al. (6) reported that
serious complications such as acute brain swelling
and delayed cerebral necrosis arose due to the high
boron content in blood and in normal brain tissue
at the site of neutron irradiation. In 1968 Hatanaka
introduced BSH as a boron carrier in Japan ; GMB
patients were subsequently treated with BNCT com-
bined with BSH and pure thermal neutrons, and this
was followed by the establishment of BSH-based
IO-BNCT which achieved good clinical results (7-
9). Laramore and Spence who analyzed the survival
data of a subset of 12 patients who had been treated
by Hatanaka between 1987 and 1994 found that
there was no differences in the survival times be-
tween that subset and patients in the RTOG-RPA
classification (19). Elsewhere we presented our clini-
cal results of IO-BNCT using BSH ; our MST was
19.5 months and the 1- and 2-year survival rate was
60.6% and 37.9%, respectively (12).
Stupp et al. (2) reported that an oral alkylating
agent, TMZ, given concomitantly with RT followed
by six 28-day cycles of TMZ alone, significantly pro-
longed the survival of GBM patients. Consequently,
the delivery of concurrent RT and TMZ became the
new standard of care for patients with newly diag-
nosed GBM. Stupp et al. (3) also reported a 5-year
analysis of their randomized RPA-subclassified
phase III EORTC-NCIC trial (RT plus concomitant
Figure 4 Kaplan Meier curves of patients treated with BNCT alone (n=7) or with RT+TMZ (n=19) who were subclassified as RPA 5.
There was no statistically significant difference between the two patient groups in the survival probability estimates (p=0.84).
BNCT, boron neutron capture therapy ; RPA, recursive partitioning analysis ; RT, radiotherapy ; TMZ, temozolomide.
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TMZ chemotherapy followed by the periodic use of
TMZ chemotherapy). Their overall MST was 14.6
months ; MST was 18.7-, 16.3-, and 10.7 months
for patients subclassified as RPA 3, RPA 4, and
RPA 5 (Table 2). Overall their 2-, 3-, and 5-year sur-
vival rates where 27.2%, 16.0% and 9.8%, respec-
tively (Table 3).
We compared the clinical results we obtained in
our RPA-subclassified patients treated with RT+
TMZ or with BNCT alone and compared our out-
comes with the results of the international EORTC-
NCIC trial. Although our study population was
smaller, our results in patients who received RT+
TMZ were similar to those reported by Stupp et al.
(2). Our patients treated with BNCT alone under-
went no additional chemotherapy ; their overall
MST was 19.5 months (Table 2) ; their 2-, 3-, and 5-
year survival rate was 31.8, 22.7 and 9.1% (Table 3).
Analysis of the clinical outcomes revealed no statis-
tically significant difference in our RPA 4 and RPA 5
patients. Furthermore, MST and the survival rate in
our patients treated with BNCT alone were compa-
rable to the findings of the EORTC-NCIC trial.
The literature contains several reports on the clini-
cal results of BNCT. Kankaanranta et al. (20) at Hel-
sinki University Central Hospital in Finland reported
22 GBM patients who suffered recurrence after re-
ceiving standard therapy. They subsequently under-
went BNCT with BPA. Their overall MST was 7
months, and the median time to disease progression
was 3 months. The aim of a phase I clinical trial per-
formed by the EORTC to evaluate BSH as a boron
delivery agent (21) was to investigate the systemic
toxicity of BSH, the tolerated radiation dose, and
the dose-limiting toxicity of BNCT. The delivery of
BNCT was in 4 fractions on 4 consecutive days. In
that trial the MST was 10.4-13.2 months for newly
diagnosed GBM patients. In a Swedish clinical trial
29 newly diagnosed GBM patients received an in-
fusion of 900 mg/kg BPA in the course of 6 hours
(22-25). The MST was 17.7 months compared to
15.5 months in patients who received standard ther-
apy comprised of surgery followed by RT and TMZ.
In Japan, Miyatake et al. (15) and Kawabata et al.
(26, 27) performed studies in which either BPA
alone or in combination with BSH was administered
as BNCT. They reported that patients treated with
surgery and BNCT using 100 mg/kg BSH and 700
mg/kg BPA infused over 6 hours, followed by 20-
30 Gy of fractionated X-rays had an MST of 23.5
months. Yamamoto et al. (28, 29) used either BPA
or BSH alone or in combination as boron delivery
agents. MST in their IO-BNCT patients who re-
ceived 100 mg/kg BSH alone was 23.3 months ;
it was 27.1 months when they administered NO-
BNCT using 100 mg/kg BSH plus 250 mg/kg BPA
followed by 30 Gy of fractionated X-rays.
Elsewhere (30) we reported our clinical results
obtained with IO-BNCT and NO-BNCT ; MST was
19.5 months and the 2-, 3-, and 5-year survival rate
was 26.1%, 17.4% and 5.8%, respectively. The data re-
viewed here show that the clinical BNCT outcome
of newly diagnosed GBM patients tended to be bet-
ter in Japan than in European series. We attribute
this to two factors in recent Japanese BNCT proce-
dure, i.e. combined use of BSH and BPA as the
boron delivery agents to obtain homogeneous accu-
mulation in tumor cells, and the delivery of addi-
tional conventional radiotherapy of 20-30 Gy after
BNCT to irradiate tumor cells that infiltrated areas
away from the tumor center.
We did not use TMZ in our patients treated with
BNCT because at the time covered by this study it
was not available in Japan. Based on our results
we expect that combination treatment of GBM pa-
tients with BNCT and adjuvant TMZ will improve
Table 3 : Comparison of the GBM survival rate in the EORTC-NCIC trial and in our patients















Overall (months) 27.2 27.5 31.8 16.0 16.5 22.7 9.8 NE 9.1
BNCT : boron neutron capture therapy, RPA : recursive partitioning analysis, RT : radiotherapy,
TMZ : temozolomide, NE : not evaluated
aStupp R et al. Effect of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma
in a randomized phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10 : 459-466, 2009
bOur study of 23 newly diagnosed GBM patients treated with BNCT. It included 17 patients treated with IO-BNCT and 6 patients treated
with NO-BNCT between 1998 and 2005. It also included 34 newly diagnosed GBM patients who were treated by external conventional
radiotherapy and temozolomide (TMZ) between 2006 and 2009 at Tokushima University Hospital.
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the outcomes of our previous institutional- and the
reported international clinical results for RT plus
TMZ.
FUTURE PERSPECTIVES
The current status of BNCT is based on reactor-
based neutron sources. It requires neutron sources
that can be installed in the hospital environment.
Low-energy particle accelerators are more appro-
priate for this purpose. The availability of this in-
strumentation in specialized health-care institutions
may determine the future of BNCT. The major ad-
vantages of accelerator-based BNCT over reactor-
based neutron sources are the possibility of their
installation in hospitals, lower radiation hazards, and
simple licensing, installation, and maintenance. At
the Kyoto University Research Reactor Institute in
Japan, a cyclotron-based neutron source has been
developed for a phase I clinical trial to treat patients
with recurrent GBM (31). We expect that in the
near future, accelerator-based BNCT may replace
treatments using reactor-based neutron sources.
CONCLUSION
Our findings show that favorable results can be
obtained in newly diagnosed GBM patients treated
by BNCT. Furthermore, patients may further bene-
fit when BNCT is combined with chemotherapeutic
agents such as TMZ. Combination therapy must be
further evaluated and definite results regarding the
survival benefits of BNCT in GBM patients require
a strictly designed phase III study.
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